Suppr超能文献

相似文献

1
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Cancer Res. 2019 Jan 15;79(2):360-371. doi: 10.1158/0008-5472.CAN-18-0781. Epub 2018 Nov 29.
2
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Blood. 2014 May 22;123(21):3286-95. doi: 10.1182/blood-2014-02-548610. Epub 2014 Mar 21.
4
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.
5
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Front Immunol. 2021 Nov 29;12:766272. doi: 10.3389/fimmu.2021.766272. eCollection 2021.
6
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.
7
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies.
Br J Pharmacol. 2019 Dec;176(23):4491-4509. doi: 10.1111/bph.14809. Epub 2019 Dec 9.
8
Noncatalytic Bruton's tyrosine kinase activates PLCγ variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.
J Biol Chem. 2020 Apr 24;295(17):5717-5736. doi: 10.1074/jbc.RA119.011946. Epub 2020 Mar 17.
9
JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL.
J Exp Med. 2025 Jan 6;222(1). doi: 10.1084/jem.20230681. Epub 2024 Nov 21.

引用本文的文献

2
IL-1 receptor antagonism reveals a yin-yang relationship between NFκB and interferon signaling in chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A. 2024 Aug 13;121(33):e2405644121. doi: 10.1073/pnas.2405644121. Epub 2024 Aug 9.
3
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Leukemia. 2024 Aug;38(8):1712-1721. doi: 10.1038/s41375-024-02301-y. Epub 2024 Jun 24.
6
Toll-like receptor 9 signaling in chronic lymphocytic leukemia cell lines.
FEBS Open Bio. 2023 Dec;13(12):2367-2374. doi: 10.1002/2211-5463.13726. Epub 2023 Nov 8.
7
MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms.
Sci Rep. 2023 Oct 6;13(1):16839. doi: 10.1038/s41598-023-44174-8.
8
In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival.
Hemasphere. 2023 Aug 23;7(9):e938. doi: 10.1097/HS9.0000000000000938. eCollection 2023 Sep.
10
The role of CD180 in hematological malignancies and inflammatory disorders.
Mol Med. 2023 Jul 17;29(1):97. doi: 10.1186/s10020-023-00682-x.

本文引用的文献

1
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.
3
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood. 2018 May 24;131(21):2357-2366. doi: 10.1182/blood-2017-12-820910. Epub 2018 Feb 26.
4
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2.
5
Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Nat Rev Cancer. 2018 Mar;18(3):148-167. doi: 10.1038/nrc.2017.121. Epub 2018 Jan 19.
6
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Clin Cancer Res. 2017 Oct 1;23(19):5814-5823. doi: 10.1158/1078-0432.CCR-17-0650. Epub 2017 Jun 23.
7
BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.
9
Chronic lymphocytic leukaemia.
Nat Rev Dis Primers. 2017 Jan 19;3:16096. doi: 10.1038/nrdp.2016.96.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验